Correspondence Address:
Upendra Nagaich
Editor, Journal of Advanced Pharmaceutical Technology and Research (JAPTR), Editor-in-Chief, SPER Times Secretary, Society of Pharmaceutical Education and Research, 22-C, Jawahar Colony, Gwalior - 474 001
India

Full Text

Dear Friends,

History had seen a transformation in molecular biology principally due to the introduction of recombinant DNA methods. These techniques have allowed the isolation and characterization of genes from any organism and determination of DNA sequence. Nowadays, a plethora of vaccines, blood factors, biopharmaceutical compounds, therapeutic proteins, enzymes, and growth factors have been developed on a grand scale. For the production of therapeutic proteins, bacteria were the agent of choice due to ease in manipulation. Afterward, yeast and mammalian cells were extensively embraced. In 1982 while discussing about the first therapeutic human protein, which was derived fr[INLINE:1]om recombinant DNA (rDNA) technology was humulin, that is, human insulin generated at Genentech, developed by Eli Lilly, and approved by the US Food and Drug Administration. Recombinant protein drugs have completely transformed the panorama for the therapy of many disorders such as many types of cancer and rheumatic conditions. In addition, the growth of 35% at an annual average rate of recombinant protein market had been witnessed since 2001, which signifies an economically healthy future for the biopharmaceutical industry. The core strategies, which have been implemented for the creation of recombinant therapeutic protein products comprises of reformulation, pegylation and other forms of modification, or the creation of analogues with different amino acid structures. The majority of these drugs are intended to have improved pharmacokinetics. The main challenge for the production of recombinant protein production is to reduce the cost of production and to improve or enhance productivity in processing of proteins. At present, the mapping of human proteins is possible which will create a juncture to completely understand the link of human diseases with genetics. In addition, bioinformatics has played a major role in bridging the gap in data evaluation between the function of protein and expression in human diseased state. While observing these situations, one can predict that the protein therapy for novel diseases would be possible by combining monoclonal antibodies and genes. Moreover, proteomics technology is gripping the field of protein identification and quantification at all stages of the development from cell line expression to protein production. Following the long discourse of development of rDNA technology, one still face the challenge to bring the modernization, to acquire pure, safe, high efficacy, and cost-effective rDNA products with quality to market.